Precision Medicine for Head and Neck Squamous Cell Carcinoma (HNSCC)

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (30 May 2022) | Viewed by 1896

Special Issue Editor


E-Mail Website
Guest Editor
Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, Changhua 500, Taiwan
Interests: head and neck cancer treatment; endoscopic surgery; basic research for head and neck
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Malignant tumors often cause cervical lymphatic metastasis. Primary cancers such as the nasopharyngeal cavity, nasal cavity, oral cavity, and throat are highly invasive and easily metastasize to the cervical lymph nodes, resulting in poor prognosis and low survival rate of patients. Therefore, a clear understanding of the mechanism by which head and neck cancer causes high invasiveness can be effectively treated. So far, the treatment strategy of surgery has been mature. In the future, it must combine multiple disciplines and medical management to ensure that patients receive the best medical services. In recent years, treatment strategies have gradually become novel, and adjuvant therapy has been found to be helpful in cancer treatment and clinical research. The current CCRT treatment policy has been steadily carried out, and further treatment with natural plants or Chinese herbal medicine can improve the therapeutic effect.

Prof. Dr. Mu-Kuan Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer medicine
  • minimally invasive endoscopic head and neck surgery
  • head and neck wound medical treatment
  • head and neck cancer surgery
  • medical imaging
  • medical management

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 3253 KiB  
Article
TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC
by Luise Klapper, Christian Idel, Patrick Kuppler, Tobias Jagomast, Amelie von Bernuth, Karl-Ludwig Bruchhage, Dirk Rades, Anne Offermann, Jutta Kirfel, Sven Perner and Julika Ribbat-Idel
J. Pers. Med. 2022, 12(6), 991; https://doi.org/10.3390/jpm12060991 - 17 Jun 2022
Cited by 6 | Viewed by 1603
Abstract
Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most common cancers in humans worldwide and have a rather poor prognosis. TRIM24 has various intracellular functions and was identified in other cancer entities as a poor prognostic factor for patients. Methods: [...] Read more.
Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most common cancers in humans worldwide and have a rather poor prognosis. TRIM24 has various intracellular functions and was identified in other cancer entities as a poor prognostic factor for patients. Methods: The expression of TRIM24 was evaluated by using immunohistochemistry. We used a large and representative cohort of 341 HNSCC patients. Data derived from immunohistochemistry evaluation was correlated with clinicopathological data from HNSCC patients. Results: The TRIM24 expression in HNSCC primary tumors is negatively correlated with the p16 status of the tumor tissues. Primary tumors of patients who developed a local recurrence were significantly more often positive for TRIM24. Kaplan–Meier analyses and Cox regression showed that patients with TRIM24 expressing tumors have significantly worse overall survival and progression-free survival and that TRIM24 expression is independent of other established risk factors. Conclusions: TRIM24 might be a new prognostic biomarker for the survival prognosis and early detection of local recurrences in HNSCC patients. It could be used for risk stratification of HNSCC patients and to identify those patients who are more prone to develop a local recurrence and therefore could profit from more frequent follow-up examinations. Full article
(This article belongs to the Special Issue Precision Medicine for Head and Neck Squamous Cell Carcinoma (HNSCC))
Show Figures

Figure 1

Back to TopTop